Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100930 · ClinicalTrials.gov registry record · NA
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
A NA study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT02100930: Completed NA study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02100930 is a NA study of Neuroblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 69 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02100930, a NA study of Neuroblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
Primary Outcome
Disease status is defined by the International Neuroblastoma Response Criteria - Complete response/remission (CR): NED; Partial response/remission: \>50% decrease in all disease parameters, exceptbone scan unchanged or improved; no more than 1 positive bone marrow site; Stable disease: \<50% decrease in all tumor markers; Progressive disease (PD): new lesion, or \>25 % increase in any disease marker.
Conditions Studied
Interventions
- BIOLOGICAL Anti-GD2 3F8 Monoclonal Antibody
- DRUG GM-CSF (granulocyte-macrophage colony-stimulating factor)
- DRUG oral isotretinoin
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-03-07 |
| Phase | NA |
What the finished NCT02100930 record still lists
NCT02100930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Anti-GD2 3F8 Monoclonal Antibody is the first listed.
NCT02100930 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02100930 about?
NCT02100930 is a clinical study titled "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma". The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
What is the current status of trial NCT02100930?
This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2014-03. Estimated completion is 2019-03-07.
What conditions does trial NCT02100930 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02100930?
The interventions under investigation include: Anti-GD2 3F8 Monoclonal Antibody (BIOLOGICAL), GM-CSF (granulocyte-macrophage colony-stimulating factor) (DRUG), oral isotretinoin (DRUG).
Who is sponsoring clinical trial NCT02100930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02100930 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02100930's enrollment target sits among peer trials
69 41st of 94 higher than 54 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
ACTIVE NOT RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia